Drug Information Association (DIA) 2020 Virtual Global Annual Meeting (June 14-18, 2020).

Clicks: 297
ID: 171766
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #16 of 29 articles by views in drugs of today (barcelona, spain : 1998)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
At the 56th Global Annual Meeting of the Drug Information Association (DIA), attendees met virtually during the height of the global COVID-19 pandemic for "rapid cross-stakeholder, cross-border collaboration" to support health worldwide. Sessions included presenters and speakers from regulatory, patient advocacy and academia sectors, with patients at the forefront of those discussions. This report covers various presentations and panel discussions from the 4-day meeting that focus on COVID-19, innovative trial designs spurred by a need to adapt amid a pandemic, digital health, novel products inspiring new regulatory standards, clinical trials, data collection and management, the need for more and better data and the ever-increasing importance of the patient perspective.
Reference Key
polychrones2020drugdrugs Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Polychrones, J;
Journal drugs of today (barcelona, spain : 1998)
Year 2020
DOI
10.1358/dot.2020.56.8.3195003
URL
Keywords
electronic health records patient-reported outcomes activ partnership decentralized clinical trials digital research networks digital health technology key risk indicators patient-focused drug development prescription drug use-related software quality tolerance limits statistical data monitoring

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.